100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series - 14/09/15
Abstract |
Background |
Patients with cutaneous melanoma metastases have experienced excellent responses to intralesional interleukin (IL)-2. This has led to its recent inclusion into the US National Comprehensive Cancer Network guidelines for management of cutaneous melanoma metastases. Despite this, intralesional IL-2 has not been highlighted in the US literature nor have US physicians adopted it.
Objective |
We sought to evaluate the effectiveness of intralesional IL-2 combined with topical imiquimod and retinoid for treatment of cutaneous metastatic melanoma.
Methods |
A retrospective case series of 11 patients with cutaneous metastatic melanoma were treated with intralesional IL-2 combined with topical imiquimod and retinoid.
Results |
A 100% complete local response rate with long-term follow-up (average of 24 months) was seen in all 11 patients treated with this proposed regimen. Biopsy specimens of treated sites confirmed absence of malignant cells. The most common treatment-related adverse event was rigors.
Limitations |
Small number of patients, retrospective review of charts, and lack of a comparison group were limitations.
Conclusion |
Intralesional IL-2 administered concomitantly with topical imiquimod and a retinoid cream is a promising therapeutic option for managing cutaneous melanoma metastases. The regimen was well tolerated and should be considered as a reasonable alternative to surgical excision.
Il testo completo di questo articolo è disponibile in PDF.Key words : imiquimod, interleukin, intralesional, metastatic melanoma, pemphigus vulgaris, retinoid
Abbreviations used : CNS, IL, MDS
Mappa
| Drs Shi and Tran contributed to the manuscript equally and are co-first authors. |
|
| Supported by Burroughs Wellcome Fund, Howard Hughes Medical Institute, National Cancer Institute (NCI P30CA093373), and the National Institute of Health (DP2-OD009752). |
|
| Conflicts of interest: None declared. |
Vol 73 - N° 4
P. 645-654 - ottobre 2015 Ritorno al numero
Articolo precedente
- Detection of mitotic figures in thin melanomas—Immunohistochemistry does not replace the careful search for mitotic figures in hematoxylin-eosin stain
- Karl Ottmann, Michael Tronnier, Christina Mitteldorf
- Genital involvement in pemphigus vulgaris (PV): Correlation with clinical and cervicovaginal Pap smear findings
- Mukaddes Kavala, Filiz Topalo?lu Demir, Ilkin Zindanci, Burce Can, Zafer Turko?lu, Ebru Zemheri, Osman Halit Cam, Ahmet Teksen
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?